# Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants

> **NCT05665647** · PHASE1 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Cohort 1: SIM0417/ritonavir and itraconazole
- **DRUG:** Cohort 2: SIM0417/ritonavir and rifampicin
- **DRUG:** Cohort 3: SIM0417/ritonavir and midazolam

## Key facts

- **NCT ID:** NCT05665647
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-29
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-02-14
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665647, "Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05665647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*